Cardiovascular Interventions Coronary Artery Disease Innovation 
DAIC
APRIL 12, 2024
Getty Images milla1cf Fri, 04/12/2024 - 20:55 April 12, 2024 — Simpson Interventions, Inc. , This designation recognizes the transformative potential of our technology in addressing a critical unmet need in the treatment of patients with coronary chronic total occlusions. Food and Drug Administration ( FDA ).
DAIC
MAY 31, 2024
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
DAIC
APRIL 5, 2024
The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need.
Cardiometabolic Health Congress
NOVEMBER 22, 2024
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Personalized Cardiometabolic Care TRANSFORM Program for Coronary Artery Disease (CAD) : The TRANSFORM program focuses on atherosclerosis-based care strategies rather than traditional risk-based approaches.
DAIC
MARCH 17, 2025
is built on more than two decades of experience, leadership and innovation in invasive cardiology to enhance cath labs and EP procedures and empower clinicians to deliver the best possible outcomes, said Jyoti Gera, CEO, CardioVascular & Interventional Solutions, GE HealthCare. AltiX AI.i
Expert insights. Personalized for you.
111 
Let's personalize your content